Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies. - Lopez JS; Milhem M; Butler MO; Thistlethwaite F; Van Tine BA; D'Angelo SP; Johnson ML; Sato T; Arkenau HT; Edukulla R; Wustner J; Marshall S; et al. (Cell reports. Medicine, 2025)